Biontech Se Stock Performance
| BNTX Stock | USD 99.27 0.31 0.31% |
The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. BioNTech returns are very sensitive to returns on the market. As the market goes up or down, BioNTech is expected to follow. At this point, BioNTech SE has a negative expected return of -0.17%. Please make sure to confirm BioNTech's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioNTech SE performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days BioNTech SE has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.31 | Five Day Return 1 | Year To Date Return (13.90) | Ten Year Return 597.12 | All Time Return 597.12 |
Dividend Date 2022-06-17 | Ex Dividend Date 2022-06-02 |
1 | Heres why vaccine stocks are surging in 2025 | 01/08/2025 |
2 | Will Non-COVID Drugs Drive PFEs Top Line in Q4 Earnings | 02/03/2025 |
3 | BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025 | 02/24/2025 |
4 | BioNTech SE Among the Best Vaccine Stocks to Buy According to Hedge Funds | 02/26/2025 |
5 | BioNTech stock falls after FDA clinical hold on malaria vaccine trial - Investing.com | 03/04/2025 |
6 | Heres Why Moderna Stock Soared 16 percent on Wednesday | 03/06/2025 |
7 | BioNTech GAAP EPS of 1.08, revenue of 1.19B | 03/10/2025 |
8 | Q4 2024 Biontech SE Earnings Call Transcript | 03/11/2025 |
9 | This biotech stock is a buy thanks to its cancer treatment pipeline, Citi says | 03/13/2025 |
10 | BioNTech Projected to Post Quarterly Earnings on Wednesday | 03/18/2025 |
| Begin Period Cash Flow | 11.7 B |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 11,308 in BioNTech SE on December 20, 2024 and sell it today you would lose (1,381) from holding BioNTech SE or give up 12.21% of portfolio value over 90 days. BioNTech SE is currently does not generate positive expected returns and assumes 3.178% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than BioNTech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0539
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BNTX |
Estimated Market Risk
| 3.18 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioNTech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding BioNTech to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0353 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 6.22 B | ||||
| Shares Outstanding | 239.97 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 8.63 X | ||||
| Revenue | 2.75 B | ||||
| Gross Profit | 2.21 B | ||||
| EBITDA | (367.1 M) | ||||
| Net Income | (677.7 M) | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 254.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 80.89 X | ||||
| Cash Flow From Operations | 207.7 M | ||||
| Earnings Per Share | (3.02) X | ||||
| Market Capitalization | 23.75 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 19.1 B | ||||
| Working Capital | 16.28 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
About BioNTech Performance
Evaluating BioNTech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 191.03 | 200.58 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.07) | (0.06) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE generated a negative expected return over the last 90 days | |
| BioNTech SE has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.75 B. Net Loss for the year was (677.7 M) with profit before overhead, payroll, taxes, and interest of 2.21 B. | |
| About 63.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: BioNTech Projected to Post Quarterly Earnings on Wednesday |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.